About HealthScout

Frequently Asked Questions

When was the trial data last updated?

Trials that started in April 2025 or earlier are included. We are currently updating data for some of the earlier trials. If a trial's eligibility criteria have changed since we processed them, you will see a notification on its page.

Who wrote the analysis and content?

An AI program turned the trials' inclusion and exclusion criteria into computer code so that a patient can be quickly matched to the right trials. This code was verified and edited if needed by an oncologist. Some analysis of trials and drugs was written by an AI and vetted by humans. See more about our team on the home page.

Where are my bookmarked trials?

Bookmarks are specific to each patient, so select the patient with the bookmarked trials and you should see them in the Trials section.

What patient information is used to match trials?

We use the following data:

Demographics (age, sex, performance status)
Cancer site, histology, and stage
Previous treatments (including chemotherapy, immunotherapy, and targeted therapies)
Biomarkers (e.g. EGFR mutation, ER status, PD-L1 expression)

Make sure to carefully review the eligibility criteria of any matched trials, since we don't have all the information about the patient.

Do you match based on specific mutations like EGFR exon 20 insertion or BRAF D594G?

We do not currently support matching based on specific mutations.

For genes with mutations that respond to targeted therapies (like tyrosine kinase inhibitors), selecting "mutation positive" assumes the patient has a responsive mutation type.
For patients with specific mutations (like EGFR exon 20 insertion or BRAF D594G), follow these steps:

First match trials with the mutation selected
Then match trials with the mutation unselected
Compare the matched trials between both scenarios
Carefully review the full eligibility criteria for any relevant trials

Can I be updated about new features and cancer types?

So glad you asked! Click here to sign up for updates.

Contact Us

[email protected]

Acknowledgements

Our team is led by Michael Gensheimer MD, a radiation oncologist at Stanford University. Thank you to Emmett Worth for help with verifying data for hundreds of clinical trials. Thank you to everyone who has given feedback on the site, including but not limited to Nathaniel Myall, Jennifer Caswell-Jin, Ali Khaki, Eunpi Cho, Joe, Elise, and Estelle Gensheimer, Doug Pereira, David R., Chitra Parikh, Abass Conteh, and Yugmel Nijjar.